S&P 500   4,535.28 (+0.35%)
DOW   35,616.65 (+0.45%)
QQQ   374.75 (-0.19%)
AAPL   148.55 (-0.14%)
MSFT   306.97 (-0.41%)
FB   340.65 (+0.19%)
GOOGL   2,839.07 (-0.90%)
TSLA   866.72 (+0.28%)
AMZN   3,412.37 (-0.92%)
NVDA   220.63 (-1.02%)
BABA   177.13 (+0.07%)
NIO   39.66 (-0.92%)
CGC   14.17 (-1.19%)
GE   104.93 (+0.19%)
AMD   116.01 (-0.28%)
MU   68.24 (+0.99%)
T   25.94 (+1.37%)
F   15.95 (+3.44%)
ACB   7.57 (+1.61%)
DIS   170.35 (-0.48%)
PFE   42.89 (+1.90%)
BA   217.06 (+0.50%)
AMC   40.92 (+0.29%)
S&P 500   4,535.28 (+0.35%)
DOW   35,616.65 (+0.45%)
QQQ   374.75 (-0.19%)
AAPL   148.55 (-0.14%)
MSFT   306.97 (-0.41%)
FB   340.65 (+0.19%)
GOOGL   2,839.07 (-0.90%)
TSLA   866.72 (+0.28%)
AMZN   3,412.37 (-0.92%)
NVDA   220.63 (-1.02%)
BABA   177.13 (+0.07%)
NIO   39.66 (-0.92%)
CGC   14.17 (-1.19%)
GE   104.93 (+0.19%)
AMD   116.01 (-0.28%)
MU   68.24 (+0.99%)
T   25.94 (+1.37%)
F   15.95 (+3.44%)
ACB   7.57 (+1.61%)
DIS   170.35 (-0.48%)
PFE   42.89 (+1.90%)
BA   217.06 (+0.50%)
AMC   40.92 (+0.29%)
S&P 500   4,535.28 (+0.35%)
DOW   35,616.65 (+0.45%)
QQQ   374.75 (-0.19%)
AAPL   148.55 (-0.14%)
MSFT   306.97 (-0.41%)
FB   340.65 (+0.19%)
GOOGL   2,839.07 (-0.90%)
TSLA   866.72 (+0.28%)
AMZN   3,412.37 (-0.92%)
NVDA   220.63 (-1.02%)
BABA   177.13 (+0.07%)
NIO   39.66 (-0.92%)
CGC   14.17 (-1.19%)
GE   104.93 (+0.19%)
AMD   116.01 (-0.28%)
MU   68.24 (+0.99%)
T   25.94 (+1.37%)
F   15.95 (+3.44%)
ACB   7.57 (+1.61%)
DIS   170.35 (-0.48%)
PFE   42.89 (+1.90%)
BA   217.06 (+0.50%)
AMC   40.92 (+0.29%)
S&P 500   4,535.28 (+0.35%)
DOW   35,616.65 (+0.45%)
QQQ   374.75 (-0.19%)
AAPL   148.55 (-0.14%)
MSFT   306.97 (-0.41%)
FB   340.65 (+0.19%)
GOOGL   2,839.07 (-0.90%)
TSLA   866.72 (+0.28%)
AMZN   3,412.37 (-0.92%)
NVDA   220.63 (-1.02%)
BABA   177.13 (+0.07%)
NIO   39.66 (-0.92%)
CGC   14.17 (-1.19%)
GE   104.93 (+0.19%)
AMD   116.01 (-0.28%)
MU   68.24 (+0.99%)
T   25.94 (+1.37%)
F   15.95 (+3.44%)
ACB   7.57 (+1.61%)
DIS   170.35 (-0.48%)
PFE   42.89 (+1.90%)
BA   217.06 (+0.50%)
AMC   40.92 (+0.29%)
NASDAQ:ARQT

Arcutis Biotherapeutics Stock Forecast, Price & News

$21.87
-0.11 (-0.50 %)
(As of 10/20/2021 02:18 PM ET)
Add
Compare
Today's Range
$21.62
$22.01
50-Day Range
$19.28
$25.50
52-Week Range
$17.51
$38.49
Volume1,007 shs
Average Volume215,115 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.15
30 days | 90 days | 365 days | Advanced Chart
Receive ARQT News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Arcutis Biotherapeutics logo

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARQT
Employees
54
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$6.20 per share

Profitability

Net Income
$-135.68 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.10 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.41 out of 5 stars

Medical Sector

176th out of 1,360 stocks

Pharmaceutical Preparations Industry

75th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Arcutis Biotherapeutics (NASDAQ:ARQT) Frequently Asked Questions

Is Arcutis Biotherapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcutis Biotherapeutics stock.
View analyst ratings for Arcutis Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Arcutis Biotherapeutics?

Wall Street analysts have given Arcutis Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcutis Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arcutis Biotherapeutics' next earnings date?

Arcutis Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arcutis Biotherapeutics
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings data on Thursday, August, 5th. The company reported ($0.84) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.94) by $0.10.
View Arcutis Biotherapeutics' earnings history
.

How has Arcutis Biotherapeutics' stock been impacted by Coronavirus?

Arcutis Biotherapeutics' stock was trading at $25.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARQT stock has decreased by 12.9% and is now trading at $21.77.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARQT?

5 brokerages have issued 12-month price objectives for Arcutis Biotherapeutics' shares. Their forecasts range from $36.00 to $80.00. On average, they expect Arcutis Biotherapeutics' share price to reach $54.40 in the next year. This suggests a possible upside of 149.9% from the stock's current price.
View analysts' price targets for Arcutis Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Arcutis Biotherapeutics' key executives?

Arcutis Biotherapeutics' management team includes the following people:
  • Mr. Todd Franklin Watanabe, Pres, CEO & Director (Age 53, Pay $734.63k) (LinkedIn Profile)
  • Dr. Bhaskar Chaudhuri, Co-Founder & Independent Director (Age 66, Pay $50.42k) (LinkedIn Profile)
  • Mr. Kenneth A. Lock, Chief Commercial Officer (Age 47, Pay $514.28k)
  • Dr. Patrick E. Burnett M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 49, Pay $619.79k)
  • Mr. Scott L. Burrows, CFO & Principal Accounting Officer (Age 44)
  • Ms. Patricia A. Turney, Sr. VP of Operations (Age 54)
  • Dr. David W. Osborne, Chief Technical Officer (Age 60)
  • Mr. Rajvir Madan, Chief Digital & Information Officer
  • Mr. Keith L. Klein, Gen. Counsel & Sec. (Age 57)
  • Ms. Courtney Barton, Chief Compliance Officer, VP, Chief of Staff & Chief Privacy Officer (Age 38)

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

What is Arcutis Biotherapeutics' stock symbol?

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hamilton Lane Advisors LLC (0.10%). Company insiders that own Arcutis Biotherapeutics stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Jonathan Silverstein, Life Sciences Viii L Frazier and Todd Franklin Watanabe.
View institutional ownership trends for Arcutis Biotherapeutics
.

Which institutional investors are selling Arcutis Biotherapeutics stock?

ARQT stock was sold by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC. Company insiders that have sold Arcutis Biotherapeutics company stock in the last year include Bhaskar Chaudhuri, Howard G Welgus, John W Smither, and Todd Franklin Watanabe.
View insider buying and selling activity for Arcutis Biotherapeutics
or view top insider-selling stocks.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcutis Biotherapeutics' stock price today?

One share of ARQT stock can currently be purchased for approximately $21.77.

How much money does Arcutis Biotherapeutics make?

Arcutis Biotherapeutics has a market capitalization of $1.09 billion. The company earns $-135.68 million in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics employs 54 workers across the globe.

What is Arcutis Biotherapeutics' official website?

The official website for Arcutis Biotherapeutics is www.arcutis.com.

Where are Arcutis Biotherapeutics' headquarters?

Arcutis Biotherapeutics is headquartered at 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361.

How can I contact Arcutis Biotherapeutics?

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The company can be reached via phone at 805-418-5006 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.